Evidence map›Paper›PMID 37079128›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2023

A convolutional neural network with self-attention for fully automated metabolic tumor volume delineation of head and neck cancer in

Pavel Nikulin, Sebastian Zschaeck, Jens Maus, Paulina Cegla, Elia Lombardo, Christian Furth, Joanna Kaźmierska, Julian M M Rogasch, Adrien Holzgreve, Nathalie L Albert and 10 more

Open access · hybridAbstract read
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 3 countries.

Pavel Nikulin *Helmholtz-Zentrum Dresden-Rossendorf, PET Center, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstrasse 400, 01328, Dresden, Germany. p.nikulin@hzdr.de.ORCID 0000-0002-4568-4018
Sebastian Zschaeck *Department of Radiation Oncology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Jens MausHelmholtz-Zentrum Dresden-Rossendorf, PET Center, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstrasse 400, 01328, Dresden, Germany.
Paulina CeglaDepartment of Nuclear Medicine, Greater Poland Cancer Centre, Poznan, Poland.
Elia LombardoDepartment of Radiation Oncology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
Christian FurthDepartment of Nuclear Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Joanna KaźmierskaElectroradiology Department, University of Medical Sciences, Poznan, Poland.
Julian M M RogaschBerlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
Adrien HolzgreveDepartment of Nuclear Medicine, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
Nathalie L AlbertDepartment of Nuclear Medicine, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
Konstantinos FerentinosDepartment of Radiation Oncology, German Oncology Center, European University Cyprus, Limassol, Cyprus.
Iosif StrouthosDepartment of Radiation Oncology, German Oncology Center, European University Cyprus, Limassol, Cyprus.
Marina HajiyianniDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Sebastian N MarschnerDepartment of Radiation Oncology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
Claus BelkaDepartment of Radiation Oncology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
Guillaume LandryDepartment of Radiation Oncology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
Witold CholewinskiDepartment of Nuclear Medicine, Greater Poland Cancer Centre, Poznan, Poland.
Jörg KotzerkeDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Frank HofheinzHelmholtz-Zentrum Dresden-Rossendorf, PET Center, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstrasse 400, 01328, Dresden, Germany.
Jörg van den HoffHelmholtz-Zentrum Dresden-Rossendorf, PET Center, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstrasse 400, 01328, Dresden, Germany.
Ludwig-Maximilians-Universität München · DEHelmholtz-Zentrum Dresden-Rossendorf · DEHumboldt-Universität zu Berlin · DEEuropean University Cyprus · CYPoznan University of Medical Sciences · PLDeutschen Konsortium für Translationale Krebsforschung · DEGreater Poland Cancer Center · PLUniversity Hospital Carl Gustav Carus · DE

Funding

Berliner Krebsgesellschaft ZSF201720Bundesministerium für Bildung und Forschung 03ZIK42
6 · The paper itself

Abstract

purposePET-derived metabolic tumor volume (MTV) and total lesion glycolysis of the primary tumor are known to be prognostic of clinical outcome in head and neck cancer (HNC). Including evaluation of lymph node metastases can further increase the prognostic value of PET but accurate manual delineation and classification of all lesions is time-consuming and prone to interobserver variability. Our goal, therefore, was development and evaluation of an automated tool for MTV delineation/classification of primary tumor and lymph node metastases in PET/CT investigations of HNC patients.

methodsAutomated lesion delineation was performed with a residual 3D U-Net convolutional neural network (CNN) incorporating a multi-head self-attention block. 698

resultsIn the cross-validation experiment, delineation of all malignant lesions with the trained U-Net models achieves DSC of 0.885, 0.805, and 0.870 for primary tumor, LN metastases, and the union of both, respectively. In external testing, the DSC reaches 0.850, 0.724, and 0.823 for primary tumor, LN metastases, and the union of both, respectively. The voxel classification accuracy was 98.0% and 97.9% in cross-validation and external data, respectively. Univariate Cox analysis in the cross-validation and the external testing reveals that manually and automatically derived total MTVs are both highly prognostic with respect to overall survival, yielding essentially identical hazard ratios (HR) (

conclusionTo the best of our knowledge, this work presents the first CNN model for successful MTV delineation and lesion classification in HNC. In the vast majority of patients, the network performs satisfactory delineation and classification of primary tumor and lymph node metastases and only rarely requires more than minimal manual correction. It is thus able to massively facilitate study data evaluation in large patient groups and also does have clear potential for supervised clinical application.

Indexed as

Head and Neck NeoplasmsPositron Emission Tomography Computed TomographyFluorodeoxyglucose F18HumansLymphatic MetastasisNeural Networks, ComputerTumor BurdenFluorodeoxyglucose F18Convolutional neural networkFDG PETHead and neck cancerHNCMetabolic tumor volumeMTV

Identifiers

PMID37079128
PMCPMC10317885
OpenAlexW4366464154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.